INFLIXIMAB THERAPY AND ITS SEROCONVERSION ADVERSE EFFECT IN INFLAMMATORY BOWEL DISEASES IN ASAMPLE OF IRAQI IN BAGHDAD HOSPITAL

Dr. Hisham Karim Fadhil* (M.B.CH.B.) and Dr. Sameer Abdulrahem Hatem (Deploma in Anesthesia)

ABSTRACT

Inflammatory bowel disease is an idiopathic chronic inflammatory disease of the gastrointestinal tract that consists of two distinct clinical entities: ulcerative colitis and Crohn’s disease (also known as a regional enteritis). The pathogenesis of the disease is not fully understood but likely involves a genetic predisposition and a dysregulated immunologic response to the local microenvironment of luminal bacteria. Ulcerative colitis (UC) and Crohn's disease (CD) represents a chronic, relapsing and remitting inflammatory condition that affects individual throughout life. UC typically presents as a recurrent bloody diarrhea and abdominal pain. It is a diffuse mucosal and submucosal disease involving only the colon, while CD is a chronic transmural disease causing inflammation in any segment of the alimentary tract. Approximate 90% of the patients have small bowel involvement and 75% of these patients have disease in the terminal ileum. These two conditions share many common features- include chronic diarrhea, bloody stools abdominal pain, gastrointestinal bleeding and weight loss.[1]

Keywords: .